Similar to VEGF blockade in our rodent GBM models, CD68+ macrophages were significantly reduced in the S/CTx/RTx/Bev group (Fig 5A and D) but not after S/CTx/RTx therapy alone (Fig 5A and D). This evidence concerns the gene CD68 and glioblastoma.